Φορτώνει......
Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models
The HER2 receptor is overexpressed in approximately 20% of breast cancers and is associated with tumorigenesis, metastasis, and a poor prognosis. Trastuzumab is a first-line targeted drug used against HER2(+) breast cancers; however, at least 50% of HER2(+) tumors develop resistance to trastuzumab....
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Sci Rep |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Nature Publishing Group
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4828666/ https://ncbi.nlm.nih.gov/pubmed/27068794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep24298 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|